Table 2. Experimental designs used for the animal studies.
Experimental animals | Group | Number of animals | Vaccine | Route | Dosage (µg) | Dose | Time-point for sera collection |
Mice | 1 | 10 | PPRV-H VLP | S.C. | 10 | 2 doses, 4 weeks apart | 1 week before immunization, 3 weeks after primary and booster immunization. |
2 | 10 | PPRV-H VLP | S.C. | 40 | 2 doses, 4 weeks apart | ||
3 | 10 | PPRV-F VLP | S.C. | 10 | 2 doses, 4 weeks apart | ||
4 | 10 | PPRV-F VLP | S.C. | 40 | 2 doses, 4 weeks apart | ||
5 | 10 | PPRV | S.C. | 10 | 2 doses, 4 weeks apart | ||
6 | 10 | PPRV | S.C. | 40 | 2 doses, 4 weeks apart | ||
7 | 10 | PBS | S.C. | / | 2 doses, 4 weeks apart | ||
Goats | 1 | 5 | PPRV-H VLP | S.C. | 300 | 2 doses, 3 weeks apart | 2 week before immunization, 3 weeks post-primary inoculation and 2,4,8, or 12 weeks post-booster inoculation. |
2 | 5 | PPRV-F VLP | S.C. | 300 | 2 doses, 3 weeks apart | ||
3 | 5 | PPRV | S.C. | 105.5TCID50 | 2 doses, 3 weeks apart | ||
4 | 5 | PBS | S.C. | / | 2 doses, 3 weeks apart |
PBS = phosphate-buffered saline; PPRV = Peste des petits ruminants virus; S.C. = subcutaneous, TCID50 = 50% tissue culture infective dose; VLP = virus-like particles.